Home > Insider Trading > Filing (0000899243-21-047829)

Filing Details

Accession Number:: 0000899243-21-047829
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-10 20:33:42
Reporting Period:: 2021-12-08

Accepted Time:: 2021-12-10 20:33:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1840233	Xilio Therapeutics Inc.	XLO	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1702921	Bcip Life Sciences Associates, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1703031	Bain Capital Life Sciences Investors, Llc	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1773187	Bain Capital Life Sciences Fund Ii, L.p.	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1796155	Bain Capital Life Sciences Investors Ii, Llc	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1818893	Bcls Ii Investco, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1819101	Bcls Ii Investo (Gp), Llc	200 Clarendon Street Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-12-08	13,458	$9.62	2,776,402	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2021-12-09	4,011	$9.84	2,780,413	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2021-12-10	21,812	$9.56	2,802,225	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2021-12-10	3,188	$10.24	2,805,413	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Footnotes

On December 8, 2021, December 9, 2021 and December 10, 2021, BCLS II Investco, LP ("BCLS II Investco") purchased 13,458, 4,011 and 25,000 shares of the Issuer's common stock, respectively.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.41 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.53 to $10.00, inclusive.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.07 to $10.00, inclusive.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.13 to $10.25, inclusive.
Represents shares of the Issuer's common stock held by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities"). Following the completion of the transactions reported in footnote (1) to this Form 4, BCLS II, BCLS II Investco and BCIPLS each holds 1,348,682, 1,292,469 and 164,262 shares of the Issuer's common stock, respectively.
Bain Capital Life Sciences Investors II, LLC ("BCLSI II") is the general partner of BCLS II. As a result, BCLSI II may be deemed to share voting and dispositive power with respect to the securities held by BCLS II. BCLSI II disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
BCLS II Investco (GP), LLC ("BCLS II Investco GP"), whose manager is BCLS II, is the general partner of BCLS II Investco. As a result, each of BCLSI II, BCLS II and BCLS II Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS II Investco. Each of BCLSI II, BCLS II and BCLS II Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Boylston Coinvestors, LLC is the general partner of BCIPLS.
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of BCLSI II and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.